INVESTOR NEWS

Nov 20, 2020

New study results confirm the value of calprotectin in management of COVID-19 patients (2020)

Moss, Norway 20.11.2020 Gentian Diagnostics AS is pleased to announce that the results from a study conducted..

Nov 05, 2020

Gentian Diagnostics divests its subsidiary PreTect AS

Gentian Diagnostics today announces the divestiture of its subsidiary PreTect AS to Mel-Mont Medical, Inc...

Oct 29, 2020

Third quarter 2020 financial report

Moss, 29 October 2020

Oct 22, 2020

Presentation of 2020 third quarter results for Gentian Diagnostics AS

Gentian Diagnostics AS will present its 2020 third quarter results on October 29th at 10.00 am.

Sep 02, 2020

Gentian Diagnostics presents at the Pareto Healthcare conference

Moss 02.09.20

Aug 27, 2020

STUDY CONFIRMS SIGNIFICANTLY ELEVATED LEVELS OF CALPROTECTIN IN PATIENTS WITH SEVERE COVID-19

Moss, 27.08.20

Aug 21, 2020

Second quarter and first half 2020 financial report

Moss, 21 August 2020

Aug 14, 2020

Presentation of second quarter and first half results for 2020 for Gentian Diagnostics AS

Gentian Diagnostics AS will present its second quarter and first half results for 2020 on August 21st at..

Jul 03, 2020

Gentian awarded up to NOK 8.0 million funding to develop a novel high-throughput COVID-19 antibody test

Moss, 3 July 2020

Jun 16, 2020

Release of BÜHLMANN fPELA® turbo

Moss 16.06.2020